Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous small-vessel vasculitis

T Lotti1, I Ghersetich, C Comacchi

  • 1Department of Dermatology, University of Florence, Italy.

Journal of the American Academy of Dermatology
|November 12, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis.

Skin health and disease·2021
Same author

Gentian violet for pyoderma gangrenosum: a retrospective chart review.

Dermatology online journal·2020
Same author

Does daily folic acid supplementation reduce methotrexate efficacy?

Dermatology online journal·2018
Same author

Treatment of skin defects with growth factors and biodegradable collagen carrier: histological evaluation in animal model.

Journal of biological regulators and homeostatic agents·2017
Same author

Cutaneous manifestations in Steinert’s disease. Apropos of four clinical cases.

Journal of biological regulators and homeostatic agents·2017
Same author

Melanin of the nipple areola complex.

Journal of biological regulators and homeostatic agents·2017
Same journal

Comparative Alopecia Outcomes After Copper and Hormonal Intrauterine Device Placement: A TriNetX Database Retrospective Cohort Study.

Journal of the American Academy of Dermatology·2026
Same journal

Uncovering a Dual Th17/Type 2 Transcriptomic Endotype in Psoriasis.

Journal of the American Academy of Dermatology·2026
Same journal

Dermatologic conditions associated with HIV among US adults across different racial and ethnic groups: A retrospective cohort study using TriNetX.

Journal of the American Academy of Dermatology·2026
Same journal

Ethical Considerations in Same-Day Surgical Treatment of a High-Risk, Poorly Differentiated Squamous Cell Carcinoma.

Journal of the American Academy of Dermatology·2026
Same journal

The Ethics of the Handshake in Dermatology.

Journal of the American Academy of Dermatology·2026
Same journal

Dermatology images: Hidradenitis suppurativa.

Journal of the American Academy of Dermatology·2026
See all related articles

Cutaneous small-vessel vasculitis (CSVV) is a condition causing palpable purpura due to inflamed venules. Treatment involves identifying and removing triggers, alongside various anti-inflammatory and immunosuppressive therapies.

Area of Science:

  • Dermatology
  • Immunology
  • Rheumatology

Background:

  • Cutaneous small-vessel vasculitis (CSVV) is a group of disorders characterized by palpable purpura.
  • It results from leukocytoclastic vasculitis affecting postcapillary venules.
  • CSVV can be idiopathic or secondary to drugs, infections, or systemic diseases.

Purpose of the Study:

  • To review the pathogenesis and treatment of cutaneous small-vessel vasculitis.
  • To highlight the diverse therapeutic strategies available for CSVV management.

Main Methods:

  • Literature review of CSVV pathogenesis and treatment modalities.
  • Analysis of immune complex involvement and later-stage pathogenetic mechanisms.

Main Results:

Related Experiment Videos

  • CSVV pathogenesis initially involves immune complexes, with lymphocytes potentially dominating later.
  • Effective treatment necessitates cause elimination (drugs, infections, allergens).

Conclusions:

  • Therapeutic options for CSVV are varied, including NSAIDs, corticosteroids, dapsone, and immunosuppressants.
  • Monoclonal antibodies may be used in severe cases.
  • Tailoring treatment to disease severity is crucial for managing CSVV.